The Attorney General of New York, Letitia James, has called on the FDA to address safety risks associated with the widely used asthma and allergy medicine Singulair (montelukast).
In a letter dated Wednesday, the state attorney general’s office emphasized the inadequacy of current warnings on the drug’s packaging, particularly concerning children.
The letter urged the FDA to conduct a comprehensive investigation into and provide warnings about the harmful neuropsychiatric side effects of Singulair.
Citing FDA’s spokesperson Chanapa Tantibanchachai’s response on Friday, Reuters stated that the agency would directly address the concerns raised by Attorney General Letitia James.
The letter referenced a Reuters report from the previous year, revealing thousands ...